Konect.ai Announces Brand Evolution: Introducing ICOM AI
Expansion in Enterprise Offerings Leads to Brand Revamp
This brand transformation arises from the company's vision to expand its enterprise offerings and align more closely with the diverse and growing needs of automotive businesses. While the change will be reflected in the design of the company's website, portal, and app, loyal users and partners can remain confident that the platform's features will stay the same, retaining the hallmark quality and reliability.
The company's CEO
Recognizing the significance of such a transition, the ICOM AI team assures its clientele, partners, and the greater public that feedback and open communication will be vital. A dedicated feedback portal and helpline will be available for all stakeholders to voice their thoughts, concerns, or suggestions during this transformative phase.
For visitors interested in finding out more about ICOM AI, formerly Konect.ai, please visit www.icom.ai.
About ICOM AI (previously Konect.ai)
ICOM AI, formerly known as Konect.ai, is a forward-thinking SaaS provider, providing an AI-powered communication platform tailored for the automotive retail sector. Utilizing advanced natural language processing, ICOM AI significantly boosts contact rates with automotive customers via immediate lead responses, persistent follow-ups, and 24/7 appointment scheduling. Aimed at elevating the customer experience and aiding clients in meeting sales targets, ICOM AI features include adept inbound lead engagement, targeted outbound SMS campaigns, and reliable after-hours support, setting a new benchmark in automotive client interactions. For more information, visit www.icom.ai
Media Contact:
Charisma! Communications
503-816-2474
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/konectai-announces-brand-evolution-introducing-icom-ai-301988662.html
SOURCE ICOM AI
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026
- EVIDENT Expands Its Pramana Digital Pathology Portfolio to Support Small and Medium-Sized Labs
- NIP Group Inc. Announces Results of Extraordinary General Meeting
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share